SPRY FY2025 EPS Estimate Decreased by Cantor Fitzgerald

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities researchers at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of ARS Pharmaceuticals in a research report issued on Thursday, May 15th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of ($1.44) for the year, down from their previous estimate of ($1.21). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share.

A number of other research analysts have also recently issued reports on SPRY. Wall Street Zen cut shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price target for the company. Oppenheimer assumed coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They set an "outperform" rating and a $40.00 price target for the company. Finally, William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $31.00.

ARS Pharmaceuticals Price Performance

NASDAQ SPRY traded up $0.46 during trading hours on Monday, reaching $14.98. 2,307,209 shares of the company's stock traded hands, compared to its average volume of 1,253,814. ARS Pharmaceuticals has a 52-week low of $7.55 and a 52-week high of $18.51. The firm has a market cap of $1.47 billion, a PE ratio of -29.37 and a beta of 0.84. The firm has a 50-day simple moving average of $13.61 and a 200 day simple moving average of $12.87.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35). The company had revenue of $7.97 million during the quarter, compared to analysts' expectations of $7.48 million.

Institutional Trading of ARS Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Alliancebernstein L.P. grew its stake in shares of ARS Pharmaceuticals by 1.1% in the first quarter. Alliancebernstein L.P. now owns 3,922,805 shares of the company's stock worth $49,349,000 after acquiring an additional 42,071 shares during the period. Vanguard Group Inc. grew its stake in shares of ARS Pharmaceuticals by 0.7% in the first quarter. Vanguard Group Inc. now owns 3,488,293 shares of the company's stock worth $43,883,000 after acquiring an additional 23,341 shares during the period. Cormorant Asset Management LP grew its stake in shares of ARS Pharmaceuticals by 220.0% in the first quarter. Cormorant Asset Management LP now owns 1,600,000 shares of the company's stock worth $20,128,000 after acquiring an additional 1,100,000 shares during the period. MPM Bioimpact LLC bought a new stake in shares of ARS Pharmaceuticals in the first quarter worth approximately $16,519,000. Finally, Alyeska Investment Group L.P. grew its stake in shares of ARS Pharmaceuticals by 903.0% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company's stock worth $13,227,000 after acquiring an additional 1,128,724 shares during the period. 68.16% of the stock is currently owned by institutional investors.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Brent L. Saunders sold 120,000 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $14.25, for a total transaction of $1,710,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Karas sold 10,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the sale, the insider now owns 7,696 shares of the company's stock, valued at approximately $107,744. This represents a 56.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 382,571 shares of company stock worth $5,177,904. 33.50% of the stock is owned by corporate insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.